semaglutide who should not take Is A Quick Fix: Bariatric Surgeon Explains The Right Way To Use It Who Should Not Take Semaglutide?

Semaglutide GLP-1 is a medication administered on a weekly basis, subcutaneously, to aid in weight loss

Genetic variants in the GLP1-related genes are linked to obesity and diabetes

The magnitude of weight loss reported in the STEP trials offers the potential for clinically relevant improvement for individuals with obesityrelated diseases

Common symptoms of this disease include yellowing of the skin (jaundice), abdominal pain, fever, nausea and vomiting

Most GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors and are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2

What makes this medication especially interesting is the shift toward oral GLP-1 therapy, offering another option for patients who may prefer not to use injectable treatments